|
|
Time |
Source |
|
Announcement
|
|
| 03 Aug 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 01 Aug 2020 |
12:35 am |
EQS
|
|
|
MorphoSys AG (0FAU) |
Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
| 31 Jul 2020 |
9:00 am |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 14 Jul 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 07 Jul 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 02 Jul 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| |
2:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 26 Jun 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 25 Jun 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 24 Jun 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 22 Jun 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 18 Jun 2020 |
3:05 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 15 Jun 2020 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 09 Jun 2020 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| |
2:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 05 Jun 2020 |
2:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 04 Jun 2020 |
2:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 28 May 2020 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| |
11:36 am |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 07 May 2020 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 06 May 2020 |
9:01 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
MorphoSys Reports First Quarter 2020 Results |
| 05 May 2020 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 04 May 2020 |
3:48 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 30 Apr 2020 |
12:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 29 Apr 2020 |
12:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 28 Apr 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 23 Apr 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 21 Apr 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 17 Apr 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 27 Mar 2020 |
12:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 23 Mar 2020 |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| |
3:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 19 Mar 2020 |
8:00 am |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 13 Mar 2020 |
5:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 05 Mar 2020 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 03 Mar 2020 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 31 Jan 2020 |
2:22 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 13 Jan 2020 |
6:32 am |
EQS
|
|
|
MorphoSys AG (0FAU) |
Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab |
| 16 Dec 2019 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 12 Dec 2019 |
4:03 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Preliminary announcement of the publication of quarterly reports and quarterly/interim statements |
| |
4:02 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] |
| 11 Dec 2019 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 05 Dec 2019 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 03 Dec 2019 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 29 Nov 2019 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 20 Nov 2019 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 18 Nov 2019 |
3:31 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis |
| 11 Nov 2019 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 06 Nov 2019 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 29 Oct 2019 |
6:38 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone |
| 28 Oct 2019 |
8:44 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Ad hoc: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility |
| 15 Oct 2019 |
4:00 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
Correction of a release from 11/10/2019 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
| 14 Oct 2019 |
12:01 pm |
EQS
|
|
|
MorphoSys AG (0FAU) |
MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China |
| 15 Nov 2016 |
10:34 pm |
GNW
|
|
|
MorphoSys AG (0FAU) |
Ad hoc: MorphoSys Raises EUR 115 million in Private Placement |
| |
4:55 pm |
GNW
|
|
|
MorphoSys AG (0FAU) |
Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares |
| 01 Oct 2016 |
10:43 am |
GNW
|
|
|
MorphoSys AG (0FAU) |
Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis |